<?xml version='1.0' encoding='utf-8'?>
<document id="30085149"><sentence text="Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs."><entity charOffset="63-73" id="DDI-PubMed.30085149.s1.e0" text="primaquine" /></sentence><sentence text="Characterization of the pharmacokinetic properties of the enantiomers of primaquine and carboxyprimaquine following administration of racemic primaquine given alone and in combination with commonly used antimalarial drugs"><entity charOffset="73-83" id="DDI-PubMed.30085149.s2.e0" text="primaquine" /><entity charOffset="88-105" id="DDI-PubMed.30085149.s2.e1" text="carboxyprimaquine" /><entity charOffset="134-152" id="DDI-PubMed.30085149.s2.e2" text="racemic primaquine" /><pair ddi="false" e1="DDI-PubMed.30085149.s2.e0" e2="DDI-PubMed.30085149.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30085149.s2.e0" e2="DDI-PubMed.30085149.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30085149.s2.e0" e2="DDI-PubMed.30085149.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30085149.s2.e1" e2="DDI-PubMed.30085149.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30085149.s2.e1" e2="DDI-PubMed.30085149.s2.e2" /></sentence><sentence text="" /><sentence text="Enantiomeric pharmacokinetics were evaluated in 49 healthy adult volunteers enrolled in three randomized cross-over studies in which a single dose of primaquine was given alone and then, after a suitable washout period, in combination with chloroquine, dihydroartemisinin/piperaquine or pyronaridine/artesunate"><entity charOffset="150-160" id="DDI-PubMed.30085149.s4.e0" text="primaquine" /><entity charOffset="240-251" id="DDI-PubMed.30085149.s4.e1" text="chloroquine" /><entity charOffset="253-271" id="DDI-PubMed.30085149.s4.e2" text="dihydroartemisinin" /><entity charOffset="272-283" id="DDI-PubMed.30085149.s4.e3" text="piperaquine" /><entity charOffset="287-299" id="DDI-PubMed.30085149.s4.e4" text="pyronaridine" /><entity charOffset="300-310" id="DDI-PubMed.30085149.s4.e5" text="artesunate" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e0" e2="DDI-PubMed.30085149.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e0" e2="DDI-PubMed.30085149.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e0" e2="DDI-PubMed.30085149.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e0" e2="DDI-PubMed.30085149.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e0" e2="DDI-PubMed.30085149.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e0" e2="DDI-PubMed.30085149.s4.e5" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e1" e2="DDI-PubMed.30085149.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e1" e2="DDI-PubMed.30085149.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e1" e2="DDI-PubMed.30085149.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e1" e2="DDI-PubMed.30085149.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e1" e2="DDI-PubMed.30085149.s4.e5" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e2" e2="DDI-PubMed.30085149.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e2" e2="DDI-PubMed.30085149.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e2" e2="DDI-PubMed.30085149.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e2" e2="DDI-PubMed.30085149.s4.e5" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e3" e2="DDI-PubMed.30085149.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e3" e2="DDI-PubMed.30085149.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e3" e2="DDI-PubMed.30085149.s4.e5" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e4" e2="DDI-PubMed.30085149.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30085149.s4.e4" e2="DDI-PubMed.30085149.s4.e5" /></sentence><sentence text=" Non-linear mixed-effects modelling was used to characterize pharmacokinetics and assess the impact of drug-drug interactions" /><sentence text="" /><sentence text="The volume of distribution of racemic primaquine was decreased by a median (95% CI) of 22"><entity charOffset="30-48" id="DDI-PubMed.30085149.s7.e0" text="racemic primaquine" /></sentence><sentence text="0% (2" /><sentence text="24%-39" /><sentence text="9%), 24" /><sentence text="0% (15" /><sentence text="0%-31" /><sentence text="5%) and 25" /><sentence text="7% (20" /><sentence text="3%-31" /><sentence text="1%) when co-administered with chloroquine, dihydroartemisinin/piperaquine and pyronaridine/artesunate, respectively"><entity charOffset="30-41" id="DDI-PubMed.30085149.s16.e0" text="chloroquine" /><entity charOffset="43-61" id="DDI-PubMed.30085149.s16.e1" text="dihydroartemisinin" /><entity charOffset="62-73" id="DDI-PubMed.30085149.s16.e2" text="piperaquine" /><entity charOffset="78-90" id="DDI-PubMed.30085149.s16.e3" text="pyronaridine" /><entity charOffset="91-101" id="DDI-PubMed.30085149.s16.e4" text="artesunate" /><pair ddi="false" e1="DDI-PubMed.30085149.s16.e0" e2="DDI-PubMed.30085149.s16.e0" /><pair ddi="false" e1="DDI-PubMed.30085149.s16.e0" e2="DDI-PubMed.30085149.s16.e1" /><pair ddi="false" e1="DDI-PubMed.30085149.s16.e0" e2="DDI-PubMed.30085149.s16.e2" /><pair ddi="false" e1="DDI-PubMed.30085149.s16.e0" e2="DDI-PubMed.30085149.s16.e3" /><pair ddi="false" e1="DDI-PubMed.30085149.s16.e0" e2="DDI-PubMed.30085149.s16.e4" /><pair ddi="false" e1="DDI-PubMed.30085149.s16.e1" e2="DDI-PubMed.30085149.s16.e1" /><pair ddi="false" e1="DDI-PubMed.30085149.s16.e1" e2="DDI-PubMed.30085149.s16.e2" /><pair ddi="false" e1="DDI-PubMed.30085149.s16.e1" e2="DDI-PubMed.30085149.s16.e3" /><pair ddi="false" e1="DDI-PubMed.30085149.s16.e1" e2="DDI-PubMed.30085149.s16.e4" /><pair ddi="false" e1="DDI-PubMed.30085149.s16.e2" e2="DDI-PubMed.30085149.s16.e2" /><pair ddi="false" e1="DDI-PubMed.30085149.s16.e2" e2="DDI-PubMed.30085149.s16.e3" /><pair ddi="false" e1="DDI-PubMed.30085149.s16.e2" e2="DDI-PubMed.30085149.s16.e4" /><pair ddi="false" e1="DDI-PubMed.30085149.s16.e3" e2="DDI-PubMed.30085149.s16.e3" /><pair ddi="false" e1="DDI-PubMed.30085149.s16.e3" e2="DDI-PubMed.30085149.s16.e4" /></sentence><sentence text=" The oral clearance of primaquine was decreased by a median of 19"><entity charOffset="23-33" id="DDI-PubMed.30085149.s17.e0" text="primaquine" /></sentence><sentence text="1% (14" /><sentence text="5%-22" /><sentence text="8%) when co-administered with pyronaridine/artesunate"><entity charOffset="30-42" id="DDI-PubMed.30085149.s20.e0" text="pyronaridine" /><entity charOffset="43-53" id="DDI-PubMed.30085149.s20.e1" text="artesunate" /><pair ddi="false" e1="DDI-PubMed.30085149.s20.e0" e2="DDI-PubMed.30085149.s20.e0" /><pair ddi="false" e1="DDI-PubMed.30085149.s20.e0" e2="DDI-PubMed.30085149.s20.e1" /></sentence><sentence text=" These interactions were enantiospecific with a relatively higher effect on (+)-S-primaquine than on (-)-R-primaquine"><entity charOffset="76-92" id="DDI-PubMed.30085149.s21.e0" text="(+)-S-primaquine" /><entity charOffset="101-117" id="DDI-PubMed.30085149.s21.e1" text="(-)-R-primaquine" /><pair ddi="false" e1="DDI-PubMed.30085149.s21.e0" e2="DDI-PubMed.30085149.s21.e0" /><pair ddi="false" e1="DDI-PubMed.30085149.s21.e0" e2="DDI-PubMed.30085149.s21.e1" /></sentence><sentence text=" No drug-drug interaction effects were seen on the pharmacokinetics of either carboxyprimaquine enantiomer"><entity charOffset="78-95" id="DDI-PubMed.30085149.s22.e0" text="carboxyprimaquine" /></sentence><sentence text="" /><sentence text="Population pharmacokinetic models characterizing the enantiospecific properties of primaquine were developed successfully"><entity charOffset="83-93" id="DDI-PubMed.30085149.s24.e0" text="primaquine" /></sentence><sentence text=" Exposure to primaquine, particularly to the (+)-S-primaquine but not the carboxy metabolites, increased by up to 30% when co-administered with commonly used antimalarial drugs"><entity charOffset="13-23" id="DDI-PubMed.30085149.s25.e0" text="primaquine" /><entity charOffset="45-61" id="DDI-PubMed.30085149.s25.e1" text="(+)-S-primaquine" /><entity charOffset="74-81" id="DDI-PubMed.30085149.s25.e2" text="carboxy" /><pair ddi="false" e1="DDI-PubMed.30085149.s25.e0" e2="DDI-PubMed.30085149.s25.e0" /><pair ddi="false" e1="DDI-PubMed.30085149.s25.e0" e2="DDI-PubMed.30085149.s25.e1" /><pair ddi="false" e1="DDI-PubMed.30085149.s25.e0" e2="DDI-PubMed.30085149.s25.e2" /><pair ddi="false" e1="DDI-PubMed.30085149.s25.e1" e2="DDI-PubMed.30085149.s25.e1" /><pair ddi="false" e1="DDI-PubMed.30085149.s25.e1" e2="DDI-PubMed.30085149.s25.e2" /></sentence><sentence text=" A better mechanistic understanding of primaquine metabolism is required for assessment of its efficacy and haematological toxicity in humans"><entity charOffset="39-49" id="DDI-PubMed.30085149.s26.e0" text="primaquine" /></sentence><sentence text="" /></document>